pharmaphorum
DECEMBER 14, 2022
But increased competition is on the horizon. Tentative approval means Lumryz has satisfied all the FDA requirements for efficacy, safety, and quality standards, but it can’t be fully approved until a patent or other exclusivity expires. Competition starts to heat up. Classic treatment options. Two decades of exclusivity.
European Pharmaceutical Review
DECEMBER 19, 2022
3 Under this pathway, comparability studies are required to substantiate the similar nature, in terms of safety and efficacy, of the biosimilar and the reference product. EMA Guideline on Similar Biological Medicinal Products, 23 October 2014, CHMP/437/04 Rev 1. The Impact of Biosimilar Competition in Europe, IQVIA, December 2021.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
SEPTEMBER 11, 2022
Analysts at Mizuho have suggested that competition from BMS’ drug could trim Otezla’s 2025 sales from $3 billion to $2 billion, although Amgen is attempting to defend its product by expanded the label of the drug to include mild psoriasis. It had been approved since 2014 for moderate to severe cases only.
European Pharmaceutical Review
FEBRUARY 7, 2023
Regulation of clinical trials Eight years following its adoption in 2014, the Clinical Trials Regulation 536/2014 (CTR) entered into application on 31 January 2022. In addition, the devices must not present an unacceptable risk to patient and user health and safety as established in Articles 94 and 95 of the MDR.
Evolve Your Success
FEBRUARY 6, 2024
He also talks about partnering with small businesses and how they are leading the competition in this particular space. I left them in 2014 to start our own thing. Patient safety is to do no harm. I finally figured some things out and broke through then did that for ten years and they blew up. Probably right around it.
European Pharmaceutical Review
JULY 1, 2022
Health and safety – the COVID-19 pandemic has thrown into sharp relief the significance of safe working environments, including the importance of employee mental health and wellbeing. Highs and lows of DEI representation in the biotech industry… Changing regulatory expectations.
Clarify Health
MARCH 15, 2023
And frankly, if you’re paying a provider 57% of the 2014 CMS schedule, they’re not going to be terribly excited about you putting this bonus program in front of them when they’re concentrating on that. We have safety net practices, which is a federally qualified health center, so FQHCs. Lisa: That’s right.
Expert insights. Personalized for you.
94 
Let's personalize your content